Antibody–drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active
cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic …

Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …

Abstract Antibody–drug conjugates (ADCs), which combine the specificity, favorable
pharmacokinetics, and biodistribution of a monoclonal antibody (mAb) with the cytotoxic …

Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy
is often associated with a low therapeutic window due to its poor specificity towards tumor …

Cancer is one of the deadliest diseases, causing million of deaths each year globally.
Conventional anti-cancer therapies are non-targeted and have systemic toxicities limiting …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Antibody drug conjugates (ADCs) consist of an antibody attached to a cytotoxic drug by
means of a linker. ADCs provide a way to couple the specificity of a monoclonal antibody …

Abstract The design of Antibody Drug Conjugates (ADCs) as efficient targeting agents for
tumor cell is still in its infancy for clinical applications. This approach incorporates the …